Good morning, everyone, and how are you today? We are just fine, thank you, especially since a shiny sun and a cool breeze are enveloping the Pharmalot campus. As the saying goes: “What’s not to like?” Of course, we are topping this off with a few cups of stimulation — hazelnut creme, if you must know — and invite you to join us. After all, this is likely to be a rather busy day. On that note, here are some tidbits. Have a good one and do keep in touch …
Sarepta Therapeutics hired Doug Ingram as its new chief executive officer, replacing Ed Kaye, who took over in 2015 as interim chief executive amid rocky negotiations with the Food and Drug Administration over its Duchenne muscular dystrophy drug. Ingram currently heads Chase Pharmaceuticals, which was bought last year by Allergan. Leerink analyst Joseph Schwartz says Ingram “brings a wealth of experience in corporate restructuring” as Sarepta seeks to solidify its leadership in DMD, and thinks this may also increase M&A speculation.
About the Author Reprints
I admire Richard Pops over at Alkermes, but this ultimatum given to addicts to take Vivitrol or face jail time. Would Ed or someone else please explain to me how this program differs in any way, shape or form from the program in England in the mid 20th century where male homosexuals were given a choice of Depo Provera injections to curb their “sexual predilections” or spend two years in prison. No difference IMO.